Board of Directors
Chairman of the Board
Ann-Charlotte Rosendahl, born in 1963, is a board member of Toleranzia since 2020. Rosendahl has over 20 years of experience in the development, commercialization and launch of drugs on the international stage. She has held senior positions withinin MSD, AstraZeneca and Roche, and has lived and worked in the United States and Switzerland for a number of years. She also has experience of strategic and operational work in biotech, as well as business development and board work. Holdings as of Dec 31, 2022: 18 750 shares (personal ownership).
Thomas Eldered, born in 1960, is a board member of Toleranzia since 2021. Eldered holds a Master's degree in Industrial Engineering and is co-founder of Recipharm AB, where he served as CEO from 2008 to 2021. He is currently chairman of the board of Amarna Therapeutics BV and Prokarium Ltd, and a member of the Board of Buzzard Pharmaceuticals AB, Chromafora AB, Flerie Invest AB, Flerie Participation AB, Kahr Medical Ltd, Nanologica AB, Provell Pharmaceutical LLC, Recipharm AB and Sixera Pharma AB, among others. Holdings as of Dec 31, 2022: 52 282 470 shares (via related party).
Maarten Kraan, born in 1961, is a board member of Toleranzia since 2018. Kraan, MD, PhD, is educated as clinical immunologist and rheumatologist and has conducted many clinical trials with many successful drugs. Kraan began in the pharmaceutical industry in 2003 and has worked in several companies such as Schering-Plow, Bristol-Myers-Squibb, Roche-Genentech and AstraZeneca. He has had different positions in research, clinical development and medical affairs. He has published a series of articles on translational medicine and is adjunct professor of rheumatology at the Sahlgrenska Academy of Gothenburg University. Holdings as of Dec 31, 2022: 232 142 shares (personal ownership).
Eva Lindgren, born in 1950, is a board member of Toleranzia since 2018. Lindgren holds a “pol mag” degree and has 40 years of experience in the pharmaceutical industry through various positions at AstraZeneca, including in project management, drug development (she has led two successful pharmaceutical projects to market and blockbuster levels), international marketing and public private partnership with other pharmaceutical companies and the European Commission. She is also a board member of IRLAB Therapeutics, the Culture Group and Lorensberg Theater. Holdings as of Dec 31, 2022: 30 868 shares (personal ownership).
Jan Mattsson, born in 1964, is a board member of Toleranzia since 2020. Mattsson, PhD, has more than 25 years of experience in the pharmaceutical industry. Jan is a co-founder of Albireo Pharma, a company listed on the US NASDAQ, which focuses on orphan liver diseases, where he is currently Chief Scientific Officer and Managing Director. Before he started Albireo in 2008, he held various leading positions in research and development at AstraZeneca. Jan has experience of research & development during all phases of drug development in a number of therapy areas but also in international business & corporate development. Holdings as of Dec 31, 2022: 10 322 shares (personal ownership).
Kristian Sandberg, born in 1961, is a board member of Toleranzia since 2017. Sandberg is an associate arofessor in immunology and an experienced leader in the pharmaceutical industry's research and development. Sandberg has been working at AstraZeneca for over 20 years in various functions, primarily with project management. He has experience in the development of both protein and conventional small molecule based drugs from concept to clinical Phase II studies, both in the field of neuroscience therapy and respiratory, inflammatory and autoimmune diseases. Sandberg is also active as a researcher at Karolinska Institutet and has had various assignments within the Foundation for Strategic Research. Since 2015, Sandberg is running the business at SciLifeLab's pharmaceutical platform at Uppsala University, whose mission is to support pharmaceutical research in Sweden. Holdings as of Dec 31, 2022: 116 071 shares (personal ownership).
Anders Waas, born in 1957, is a board member of Toleranzia since 2017. Waas has more than 25 years of experience in the pharmaceutical, biotechnology and medical technology industry, including global business development, commercialization and product development. As previously Vice President Business Development for CV Therapeutics, USA, he has many years of commercial and business development experience from the US market. Within AstraZeneca, Waas has held a number of senior positions and, among other things, been responsible for commercial product strategy and global product launch in cardiovascular, metabolic and gastrointestinal disease. He has also been globally responsible for business development in cardiovascular and metabolic disease. Waas also has experience from medical technology product development and commercialization from his time at WL Gore & Associates. Most recently, Waas was the CEO of TikoMed. Holdings as of Dec 31, 2022: 0 shares.
Klementina Österberg, born in 1975, is a board member of Toleranzia since 2012. Österberg is the CEO of GU Ventures AB, Gothenburg University's holding company, which operates an incubator and invests in the commercialization of innovations. Österberg is a graduate in business administration and works actively with financing, business start-ups and corporate management in companies in the GU Ventures AB sphere. Previous assignments include Venture Cup, various Volvo companies, Daimler Chrysler and Geveko Industries. Holdings as of Dec 31, 2022: 238 575 shares (personal ownership and via related party).